is enzalutamide approved by fda?
On December 16, 2019, the Food and Drug Administration approved enzalutamide (XTANDI, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC). FDA previously approved enzalutamide for patients with castration-resistant prostate cancer.